Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care Poster Display session

208P - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)

Presentation Number
Lecture Time
12:45 - 12:45
  • Anees Hassan (Dublin, IE)
Hall A3 - Poster Area Networking Hub, ICM M√ľnchen, Munich, Germany
12:45 - 13:45



The 21 gene RS has improved the selection of patients (pts) for ChemoRx in early BC. Internationally, the RS is used in LN+ disease, but has not been reimbursed for this indication in Ireland. We conducted a prospective study to determine the extent to which use of the RS could alter Oncologists’ ChemoRx recommendations in pts with LN+ BC.


Eligible patients had 1-3 LN+, HR+ HER2- BC. All pts gave written informed consent. Baseline demographics were collected. Questionnaires were completed by a Consultant Oncologist before and after the RS, which examined expectations of tumour chemo-sensitivity, strength of ChemoRx recommendation and type of planned ChemoRx. The primary endpoint was the % reduction in pts recommended ChemoRx (N = 75).


RS was available on 74/75 pts; median age 54 (range 32-78) years. Most pts had T1 (43%) / T2 (47%), grade 2 (72%) tumours with 1 LN + (68%). The RS was <11 in 10 (13%), 11-25 in 56 (76%) and >25 in 8 (11%) pts. Access to the RS led to a 27% reduction in ChemoRx recommendations from 68 (92%) to 48 (65%) pts. This was most notable in pts with 1 LN + (46 vs 24) and 2 LN + (13 vs 7). Access to the RS led to a reduction in physician perception of tumour chemosensitivity and strength of ChemoRx recommendation (Table). Use of the RS led to a decrease in Anthracycline (A)-Taxane (T) ChemoRx (30 vs 17 pts) and T-based ChemoRx (30 vs 21 pts) with a resultant increase in non-A, non-T ChemoRx (8 vs 10 pts). The use of the RS did not impact on ChemoRx recommendations in women <40yrs (all got ChemoRx). The biggest reduction in ChemoRx occurred in women age 51-70 with 1LN + (28 vs 18 pts). Overall, in 47 (64%) cases, Oncologists thought the RS significantly changed their treatment recommendations.

Physician questionnaires before and after RS
1. How sensitive will the tumour be to ChemoRx?
Not very sensitiveVery sensitive
Before RS
10 (13)32 (43)21 (28)10 (13)1 (1)
After RS
21 (28)26 (35)15 (20)11 (15)5 (7)
2. How strongly do you recommend ChemoRx?
Not very stronglyVery strongly
Before RS
7 (9)22 (30)20 (27)20 (27)5 (7)
After RS
23 (31)16 (22)10 (13)21 (28)4 (5)


Broader access to the 21 gene RS could result in a reduction in the use of ChemoRx in Ireland.

Legal entity responsible for the study

Cancer Trials Ireland.


Genomic Health Company.


P.G. Morris: Honoraria: Genomic Health Company. All other authors have declared no conflicts of interest.